Search

Your search keyword '"Rubin, Brian P"' showing total 203 results

Search Constraints

Start Over You searched for: Author "Rubin, Brian P" Remove constraint Author: "Rubin, Brian P" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
203 results on '"Rubin, Brian P"'

Search Results

4. Surgical Margins in Musculoskeletal Sarcoma

9. Machine learning for rhabdomyosarcoma histopathology

11. A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma

13. Correction to: Machine learning for rhabdomyosarcoma histopathology

23. Data from NSD3–NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism

24. Supplementary Figure 4 from NSD3–NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism

25. Supplementary Methods, Figure Legends 1-4 from Evasion Mechanisms to Igf1r Inhibition in Rhabdomyosarcoma

26. Supplementary Figure 3 from NSD3–NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism

27. Supplementary Figures 1-9 from The Long Noncoding RNA NEAT1 Promotes Sarcoma Metastasis by Regulating RNA Splicing Pathways

28. Supplementary Figure 2 from NSD3–NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism

29. Supplementary Tables 1-6 from The Long Noncoding RNA NEAT1 Promotes Sarcoma Metastasis by Regulating RNA Splicing Pathways

30. Supplementary Figure 1 from NSD3–NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism

31. Data from The Long Noncoding RNA NEAT1 Promotes Sarcoma Metastasis by Regulating RNA Splicing Pathways

32. Data from Evasion Mechanisms to Igf1r Inhibition in Rhabdomyosarcoma

33. Supplementary Figures 1-4 from Evasion Mechanisms to Igf1r Inhibition in Rhabdomyosarcoma

35. Data from Immune Competency of a Hairless Mouse Strain for Improved Preclinical Studies in Genetically Engineered Mice

37. Supplementary Figure 3 from Immune Competency of a Hairless Mouse Strain for Improved Preclinical Studies in Genetically Engineered Mice

38. Supplementary Tables 1-5, Supplementary Figures 1-6 from Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α

39. Supplementary Supplementary Methods, Supplementary Tables 1-6, Supplementary Figures 1-9 from Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

40. Supplementary Figure 1 from Immune Competency of a Hairless Mouse Strain for Improved Preclinical Studies in Genetically Engineered Mice

41. Supplementary Figure 2 from Immune Competency of a Hairless Mouse Strain for Improved Preclinical Studies in Genetically Engineered Mice

42. Supplementary Figure 4 from Credentialing a Preclinical Mouse Model of Alveolar Rhabdomyosarcoma

44. Supplementary Tables 1-7 from Credentialing a Preclinical Mouse Model of Alveolar Rhabdomyosarcoma

45. Supplementary Figure 1 from Credentialing a Preclinical Mouse Model of Alveolar Rhabdomyosarcoma

47. Supplementary Figure 2 from Credentialing a Preclinical Mouse Model of Alveolar Rhabdomyosarcoma

48. Data from Credentialing a Preclinical Mouse Model of Alveolar Rhabdomyosarcoma

49. Supplementary Table 8 from Credentialing a Preclinical Mouse Model of Alveolar Rhabdomyosarcoma

50. Supplementary Figure Legends 1-5 from Credentialing a Preclinical Mouse Model of Alveolar Rhabdomyosarcoma

Catalog

Books, media, physical & digital resources